Lung Cancer FAQs
Your questions about lung cancer screening, answered
Lung cancer is the leading cause of cancer death in the United States. Screening saves lives, but most people who qualify don't know they do. We've answered the most common questions below.
1 in 19
Americans will be diagnosed with lung cancer in their lifetime
30%
5-year survival rate overall, rising to 65% when caught early
80%
Of eligible high-risk Americans are not currently being screened
50 to 80
Age range recommended for annual LDCT screening under USPSTF guidelines
Section 1
Lung Cancer Basics
Lung cancer is a disease in which malignant cells form in the tissues of the lung. It is the leading cause of cancer death in the United States for both men and women. While smoking is the primary cause, lung cancer can develop in people who have never smoked. Risk factors include cigarette, pipe, or cigar smoking; secondhand smoke exposure; radon gas (the second most common cause after smoking); air pollution; occupational exposures to asbestos or other chemicals; and personal or family history of lung cancer.
Lung cancer is the second most common cancer in the US and the leading cause of cancer death. Approximately 229,000 new cases are diagnosed each year, and roughly 125,000 Americans die from it annually, about as many as breast, prostate, and colorectal cancers combined. About 1 in 19 Americans will be diagnosed with lung cancer in their lifetime.
About 3 in 10 people are alive 5 years after a lung cancer diagnosis, but this number varies dramatically based on when cancer is caught. When found early, before it has spread beyond the lung, the 5-year survival rate is about 65%. Once it has spread to distant organs, it falls to about 10%. Unfortunately, only about 1 in 4 lung cancers is caught at that early, localized stage, and about 7 in 10 are found after the cancer has spread. This is exactly why screening matters.
The highest-risk individuals are current and former smokers, particularly those with heavy smoking histories. Additional risk factors include radon gas exposure in the home, occupational exposure to asbestos, arsenic, chromium, or diesel fumes, a personal or family history of lung cancer, chronic obstructive pulmonary disease (COPD), and long-term secondhand smoke exposure. Black men have the highest lung cancer incidence rate in the US.
Pack-years measure the total amount of cigarettes someone has smoked over their lifetime. You calculate it by multiplying packs per day by years smoked. For example: 1 pack per day for 20 years = 20 pack-years. Current USPSTF screening guidelines require a minimum 20 pack-year history to qualify for annual low-dose CT screening.
Yes. Approximately 20% of lung cancer cases occur in people who have never smoked, making it the 6th leading cause of cancer death among non-smokers alone. These cases are typically linked to radon gas, secondhand smoke, air pollution, occupational exposures, or family history.
Significant disparities exist in lung cancer outcomes. Black Americans, low-income individuals, and those in rural communities are less likely to be diagnosed at an early stage, less likely to receive curative treatment, and more likely to die from lung cancer. Access to screening is a major driver of these disparities. That is why Oatmeal Health focuses specifically on bringing screening to FQHCs serving underserved communities.
Section 2
Who Should Be Screened
Criteria 1
50 to 80 years old
Criteria 2
20+ pack-year smoking history
Criteria 3
Currently smoke or quit within the last 15 years
If you meet these criteria, annual LDCT screening is covered at no cost by most private insurance plans, and by Medicare for ages 50 to 77.
LDCT stands for Low-Dose Computed Tomography. It is a specialized CT scan that takes detailed cross-sectional images of your lungs using significantly less radiation than a standard diagnostic CT scan. LDCT is quick (typically under 10 minutes), painless, non-invasive, and requires no injections or contrast dye.
The USPSTF updated its screening guidelines in 2021, giving lung cancer screening a Grade B recommendation. The updated criteria: ages 50 to 80, at least a 20 pack-year smoking history, and currently smoking or having quit within the past 15 years. These guidelines expanded eligibility significantly from the 2013 version.
Yes, significantly. The NLST showed that LDCT reduced lung cancer mortality by 20% compared to chest X-ray. 57% of the lung cancers found in the low-dose CT group were early stage (stage I or II), compared with 39% in the chest X-ray group.
According to USPSTF guidelines, screening should be discontinued when you turn 81, you have not smoked for more than 15 years, or you develop a health problem that substantially limits your life expectancy.
Quitting smoking is the single most important thing you can do to reduce your lung cancer risk, but former smokers remain at elevated risk for many years after quitting. The USPSTF recommends screening for anyone who quit within the past 15 years.
Annual (yearly) screening is recommended for all eligible individuals. If a nodule is detected, your radiologist may recommend more frequent follow-up scans at 3 or 6 month intervals.
80%
Of eligible high-risk Americans are not being screened for lung cancer today
Section 3
The Screening Process
1
Talk to your doctor
Discuss your eligibility and get a referral or order for LDCT screening.
2
Schedule your scan
Book at a certified lung cancer screening center. Most appointments take under 30 minutes.
3
The LDCT scan
You lie still on a table while the scanner takes images. No injections, no contrast dye. Under 10 minutes.
4
Get your results
A radiologist reviews your images and sends results to your doctor, typically within 1 to 2 weeks.
Preparation is minimal. You can eat and drink normally. Wear comfortable, loose-fitting clothing without metal. No contrast dye or injection is involved.
You lie on a motorized table that slides through a ring-shaped CT scanner. The scan takes less than 10 minutes and the actual image capture is under 30 seconds. You hold your breath briefly (about 6 seconds). No pain, no injections.
LDCT uses about 1.5 millisieverts of radiation, roughly 75% less than a standard chest CT and about the same as 6 months of natural background radiation. For high-risk individuals, the benefit of early detection far outweighs the small theoretical risk.
CT scanners are much more open than MRI machines. The ring opening is wide (typically 70cm) and the scan is very short. Most claustrophobic patients find it tolerable. Tell your doctor beforehand if you have significant anxiety.
Results are typically available within 1 to 2 weeks. Your physician will contact you to review results. If anything urgent is found, you may be contacted sooner.
Screening must be performed at an ACR designated lung cancer screening center. Your primary care doctor, FQHC, or community health center can provide a referral. Oatmeal Health partners with FQHCs to connect patients to accredited screening programs.
In most cases, yes. Medicare requires a written order from a physician along with a shared decision-making visit before your first screening. Some community health programs, including those supported by Oatmeal Health at FQHCs, streamline this process.
A low-dose CT scan takes less than a minute and uses 75% less radiation than a standard CT
< 60 seconds
Average scan time
No IV contrast
No needles, no dye injection
$0 copay
For eligible patients with insurance
Section 4
Results and Next Steps
Most common result
Negative: No significant findings
No suspicious nodules detected. Continue with annual screening next year.
Requires follow-up
Nodule found: Additional imaging needed
A pulmonary nodule was detected. Most nodules are benign. Follow-up scans determine whether the nodule is growing.
Least common result
Suspicious finding: Further evaluation
A finding is highly suspicious. Your doctor will refer you to a specialist for biopsy and treatment planning.
Your radiologist reports results using Lung-RADS scoring. Scores range from 0 to 4: Category 1 = no nodules, return next year. Category 2 = very low likelihood of malignancy. Category 3 = probably benign, 6-month follow-up. Category 4A and 4B = suspicious findings needing additional imaging or tissue sampling.
A pulmonary nodule is a small, rounded growth in the lung, typically less than 3cm. The vast majority are benign. In the NLST, about 96% of positive results turned out not to be cancer. A nodule finding triggers monitoring, not automatic diagnosis.
The Fleischner Society provides evidence-based recommendations based on nodule size, composition, and patient risk. Solid nodules smaller than 6mm in low-risk patients typically require no follow-up. Larger nodules may need follow-up CT, PET scan, or tissue sampling.
A false positive is when a scan detects something that requires follow-up but turns out not to be cancer. In the NLST, approximately 96.4% of positive results were false positives. Most are resolved through non-invasive follow-up scans.
Your doctor will refer you to a pulmonologist or thoracic surgeon. Additional steps typically include a PET scan and tissue biopsy. If cancer is confirmed, treatment may include surgery, radiation, chemotherapy, immunotherapy, or targeted therapy. Cancer found early is far more likely to be curable.
LDCT may detect findings unrelated to lung cancer, including emphysema, coronary artery calcification, aortic aneurysm, or enlarged lymph nodes. Your radiologist will note relevant incidental findings and your doctor will advise on follow-up.
Section 5
Cost and Insurance
Coverage type
Medicare
100% covered, $0 out of pocket
Medicare Part B covers annual LDCT at no cost for eligible beneficiaries.
Coverage type
Private Insurance
Covered under ACA preventive care
The ACA requires most private insurers to cover USPSTF Grade B recommendations at no cost sharing.
Coverage type
Uninsured
Low cost options available at FQHCs
Sliding scale fees based on income.
Yes. Medicare Part B covers annual LDCT at no cost (no deductible, no coinsurance, no copay) for eligible beneficiaries ages 50 to 77 with at least a 20 pack year history who currently smoke or quit within 15 years. The shared decision making visit is also covered.
Under the ACA, most private plans must cover USPSTF Grade B services at no cost when using an in network provider. Grandfathered plans may not be required to cover it. Always verify with your insurer.
Coverage varies by state. Most states cover it through Medicaid, but specifics differ. Contact your state Medicaid program to confirm.
FQHCs serve all patients regardless of insurance status using a sliding fee scale. Some hospital systems offer free or reduced cost screening programs. Oatmeal Health partners with FQHCs to connect uninsured patients to screening.
For most ACA compliant plans, prior authorization should not be required. Some Medicaid or grandfathered plans may require it. Confirm with your insurer beforehand.
The screening scan itself should be free. However, follow up diagnostic CTs, biopsies, PET scans, and specialist visits may be billed as diagnostic procedures with cost sharing. Ask your provider upfront.
What AI sees that the human eye might miss
LungAI works alongside the computer-aided detection (CADe) software radiologists already use. For every nodule it finds, LungAI adds a 0 to 100 malignancy score, an AI second opinion on every lung screening CT.
Works inside your CADe viewer
0 to 100 malignancy score
AI second opinion
Radiologist decision support
LungAI is investigational and not FDA cleared.
Section 6
AI in Screening
Nodule detection
FDA-cleared AI software can flag and measure lung nodules, typically 3 mm and larger, acting as a second set of eyes for the radiologist.
Risk stratification
AI models assess nodule characteristics, growth patterns, and patient risk factors to prioritize urgent findings.
Expanding access
AI tools help community health centers find eligible patients and manage referrals, bringing screening to underserved communities.
AI is used across the screening workflow: finding eligible patients in health records, helping radiologists detect and measure nodules, estimating how likely a nodule is to be cancer, and tracking follow-up. Oatmeal Health works on both ends: finding the patients who qualify, and giving radiologists an AI second opinion on their scans.
No. AI assists radiologists as a second reader or decision support system. A board-certified radiologist still reviews your scan, makes the decisions, and signs the final report.
Results vary by tool and by study. Studies show AI can help radiologists find nodules they might otherwise miss, but AI is not perfect: it also flags findings that turn out to be nothing, and it is always used as decision support within a radiologist-led workflow.
Oatmeal Health has two products. LungIQ finds patients in a health center's records who qualify for screening but have not been screened, and helps care teams refer them. LungAI gives radiologists a 0 to 100 malignancy score for every nodule on a lung screening CT, inside the viewer they already use. LungAI is investigational and not FDA cleared.
Several AI tools for lung nodule detection have received FDA clearance through the 510(k) pathway. Oatmeal Health's LungAI is investigational and not FDA cleared; it is being developed for a 510(k) submission.
Yes. Only about 20% of eligible Americans are screened. AI can identify eligible patients in health records, make it easier for providers to start screening conversations, and help keep referrals from falling through the cracks.
Section 7
Common Myths
Myth
"I quit smoking years ago, I don't need to be screened."
Fact
Former smokers remain at significantly elevated risk for many years. The USPSTF recommends screening for anyone who quit within the past 15 years.
Myth
"If I had lung cancer, I would feel it."
Fact
Early stage lung cancer typically causes no symptoms at all. Symptoms usually appear only once cancer has grown or spread.
Myth
"Lung cancer only happens to heavy smokers."
Fact
About 10% to 20% of lung cancers occur in people who have never smoked. Radon, secondhand smoke, air pollution, and occupational exposures all contribute.
Myth
"A chest X ray is good enough to detect lung cancer."
Fact
LDCT reduced lung cancer mortality by 20% compared to chest X ray in the NLST. X rays cannot detect the small nodules LDCT can find.
Myth
"If a nodule is found, it probably means I have cancer."
Fact
Roughly 96% of positive screening results are not cancer. Most nodules are from past infections, scar tissue, or small lymph nodes.
Myth
"Lung cancer screening is expensive and not covered by insurance."
Fact
Annual LDCT is covered at no cost under Medicare and most ACA compliant plans. FQHCs offer sliding scale access for uninsured patients.
Myth
"There's nothing you can do about lung cancer, so why screen?"
Fact
When caught early, the 5-year survival rate is about 65%, compared to about 10% once it has spread to distant organs. Early stage lung cancer is highly treatable.
Take the next step
Find out if you qualify for free lung cancer screening
If you are between 50 and 80 years old with a 20+ pack-year smoking history and currently smoke or quit within the last 15 years, you may qualify for annual LDCT screening at no cost. Talk to your doctor or visit your nearest FQHC to get started.
LungAI is investigational and not FDA cleared.